Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>m<sup>6</sup>A modification affects the pathological progress of many diseases by affecting RNA stability and translocation. YTHDC2, a m<sup>6</sup>A reader, is associated with multiple cancers; however, little is known of its role in non‐small cell lung cancer (NSCLC). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>The GEPIA, Oncomine and GEO databases were analyzed to assess expression of <i>YTHDC2</i> in NSCLC patients. Quantitative polymerase chain reaction, western blot and immunohistochemistry were used to detect YTHDC2 expression in different NSCLC cell lines (H1299, H460, H292 and A549) and patients. The effects of YTHDC2 on NSCLC cell lines (A549 and H1299) proliferation and migration were employed using CCK8 and transwell assays. The potential target RNAs of YTHDC2 were obtained from the POSTAR database. Functional enrichment analysis of YTHDC2 targeted RNAs was performed using the Metascape database. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>GEPIA, Oncomine and GEO databases showed low expression of <i>YTHDC2</i> in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients. YTHDC2 expression was significantly decreased in different NSCLC cell lines and our clinical samples. Moreover, low expression of YTHDC2 was significantly associated with poor differentiation, lymph node metastasis, tumor size and stage. In addition, YTHDC2 could suppress the proliferation and migration ability of A549 and H1299 cell lines. Kaplan‐Meier Plotter database analysis revealed that patients with low level of YTHDC2 had a significantly poor prognosis. Finally, functional enrichment analysis of YTHDC2 targeted RNAs indicated several enriched pathways related to cancer. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>These findings elucidate that YTHDC2 suppresses tumorigenesis in NSCLC, indicating that YTHDC2 may be a promising therapeutic target for NSCLC.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significant findings of the study</h3><p>This study demonstrated that the downregulation of YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer (NSCLC).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> What this study adds</h3><p>YTHDC2 might be a promising therapeutic target for non‐small cell lung cancer (NSCLC).</p></section>

Downregulation of m6A Reader YTHDC2 Promotes the Proliferation and Migration of Malignant Lung Cells via CYLD/NF-κB Pathway.

Downregulation of m<SUP>6</SUP>A Reader YTHDC<SUP>2</SUP> Promotes the Proliferation and Migration of Malignant Lung Cells via CYLD/NF-B Pathway

Downregulation of m6A reader YTHDC2 promotes the proliferation and migration of lung cancer and cigarette smoke-exposed BEAS-2B cells

Downregulation of M6a Reader YTHDC2 Promotes Tumor Progression and Predicts Poor Prognosis in Non‐small Cell Lung Cancer

The m6A Reader YTHDC2 Suppresses Lung Adenocarcinoma Tumorigenesis by Destabilizing MRPL12

Cigarette smoking induces aberrant N6-methyladenosine of DAPK2 to promote non-small cell lung cancer progression by activating NF-κB pathway

Downregulation of <scp> m <sup>6</sup> A </scp> reader <scp>YTHDC2</scp> promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer

Downregulation of m 6 A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer

The m6A Reader YTHDF1 Promotes Lung Carcinoma Progression via Regulating Ferritin Mediate Ferroptosis in an m6A-Dependent Manner

Downregulation of the m6A reader YTHDC2 upregulates exosome content in lung adenocarcinoma via inhibiting IFIT and OAS family members

YTHDF2 Inhibits the Migration and Invasion of Lung Adenocarcinoma by Negatively Regulating the FAM83D-TGFβ1-SMAD2/3 Pathway

METTL3-mediated M6a Modification of ZBTB4 Mrna is Involved in the Smoking-Induced EMT in Cancer of the Lung.

The m6A reader YTHDC2 inhibits lung adenocarcinoma tumorigenesis by suppressing SLC7A11-dependent antioxidant function

M6A reader YTHDF1 promotes malignant progression of laryngeal squamous carcinoma through activating the EMT pathway by EIF4A3

YTH domain family protein 3 accelerates non-small cell lung cancer immune evasion through targeting CD8+ T lymphocytes

YTHDF3-mediated m6A modification of NKD1 regulates hepatocellular carcinoma invasion and metastasis by activating the WNT/β-catenin signaling axis

lncRNA ZNRD1-AS1 promotes malignant lung cell proliferation, migration, and angiogenesis via the miR-942/TNS1 axis and is positively regulated by the m6A reader YTHDC2

Smoking‐Induced M2‐TAMs, via circEML4 in EVs, Promote the Progression of NSCLC through ALKBH5‐Regulated m6A Modification of SOCS2 in NSCLC Cells

RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/β-catenin signaling

RETRACTED: METTL3-mediatedm6Amodification Ofzbtb4mrna is Involved in the Smoking-Induced EMT in Cancer of the Lung (retracted Article)

Cigarette smoking, by accelerating the cell cycle, promotes the progression of non-small cell lung cancer through an HIF-1α-METTL3-m 6 A/CDK2AP2 axis